BCL2L1 Recombinant Monoclonal Antibody

說明書

中文名稱：

BCL2L1重組抗體
貨號：

CSB-RA247982A0HU
規(guī)格：

￥1320
圖片：
Western Blot
Positive WB detected in: K562 whole cell lysate, Hela whole cell lysate, NIH/3T3 whole cell lysate, Rat Brain whole cell lysate, Mouse Brain whole cell lysate
All lanes: Bcl-XL antibody at 1:1000
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 27, 19, 26 kDa
Observed band size: 30 kDa

IHC image of CSB-RA247982A0HU diluted at 1:100 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關產(chǎn)品
靶點詳情

產(chǎn)品詳情

產(chǎn)品描述：

BCL2L1重組單克隆抗體（CSB-RA247982A0HU）是一種高特異性抗體，靶向調(diào)控細胞凋亡的關鍵蛋白BCL2L1（Bcl-2樣蛋白1）。該蛋白屬于BCL-2家族成員，通過抑制線粒體途徑的凋亡信號參與多種生理與病理過程，包括癌癥發(fā)生、神經(jīng)退行性疾病及免疫調(diào)節(jié)等。本抗體經(jīng)ELISA、蛋白質(zhì)印跡（WB）及免疫組織化學（IHC）嚴格驗證，在不同實驗體系中均表現(xiàn)出優(yōu)異的靈敏度和特異性。在WB實驗中，推薦使用1:500至1:5000的稀釋比例，可清晰檢測目標蛋白表達；IHC實驗推薦1:50至1:200稀釋，適用于石蠟包埋或冰凍組織切片的定位分析。該產(chǎn)品適用于細胞凋亡機制研究、腫瘤微環(huán)境分析、藥物靶點篩選等科研領域，尤其為探究BCL2L1在疾病模型中的功能調(diào)控提供可靠工具。其重組單克隆特性確保批次間一致性，結合優(yōu)化的緩沖體系，可在多種樣本類型中實現(xiàn)穩(wěn)定重復的實驗結果，滿足基礎研究與轉(zhuǎn)化醫(yī)學的多元化需求。
Uniprot No.：

Q07817
基因名：

BCL2L1
別名：

Bcl-2-like protein 1 (Bcl2-L-1) (Apoptosis regulator Bcl-X), BCL2L1, BCL2L BCLX
反應種屬：

Human, Mouse, Rat
免疫原：

A synthesized peptide derived from human Bcl-XL
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號：

5E9
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
產(chǎn)品提供形式：

Liquid
應用范圍：

ELISA, WB, IHC

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:5000
IHC	1:50-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

功能：

Potent inhibitor of cell death. Inhibits activation of caspases. Appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.; Isoform Bcl-X(L) also regulates presynaptic plasticity, including neurotransmitter release and recovery, number of axonal mitochondria as well as size and number of synaptic vesicle clusters. During synaptic stimulation, increases ATP availability from mitochondria through regulation of mitochondrial membrane ATP synthase F(1)F(0) activity and regulates endocytic vesicle retrieval in hippocampal neurons through association with DMN1L and stimulation of its GTPase activity in synaptic vesicles. May attenuate inflammation impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release.; Isoform Bcl-X(S) promotes apoptosis.
基因功能參考文獻：
1. Study shows that multiple ion transporters mediate the rise in pH that increases the rate of Bcl-xL deamidation in response to DNA damage in certain cells. Additionally, deamidation of Bcl-xL is intramolecularly catalyzed in a manner that is dependent upon two conserved histidines near each of the deamidation sites and that they may function together as a pH-sensitive switch. PMID: 29694915
2. hTERT contains a BH3-like motif, a short peptide sequence found in BCL-2 family proteins, and interacts with anti-apoptotic BCL-2 family proteins MCL-1 and BCL-xL PMID: 29937479
3. Study demonstrated that lncRNA-HEIH regulates miR-939 expression through transcriptional repression of Bcl-xL promoting colorectal tumorigenesis. PMID: 29081216
4. Results showed that the expressions of RIP2 and BclxL were positively correlated with the malignant grade of astrocytoma. RIP2 promoted human glioblastoma cell proliferation by inducing expression of BclxL. PMID: 29693188
5. BCL-XL has a role in modulating RAS signalling to favor breast cancer cell stemness PMID: 29066722
6. Bcl-xL degradation during endoplasmic reticulum stress-induced apoptosis is mediated by RNF183.RNF183 ubiquitinates Bcl-xL. PMID: 29507230
7. BCL-XL promotes stemness and contributes to the aggressiveness of both melanoma and glioblastoma. PMID: 29238043
8. inhibition of the BCL2 family member BCLxL resulted in nanomolar potency against human synovial sarcoma cell lines and 50% tumor reduction in a genetically engineered mouse model PMID: 28851813
9. inhibition of Bcl-xL induces significantly more apoptosis in IDH1-mutated cells than in wild-type IDH1 cells. PMID: 29057925
10. CCAT1 is upregulated in docetaxel-resistant lung adenocarcinoma cells; its oncogenic function depends on sponging of let-7c, which releases Bcl-xl, promoting the acquisition of chemoresistance and epithelial-to-mesenchymal transition phenotypes PMID: 27566568
11. In the epithelial ovarian cancer stem cells, 40% knock-down of Bclxl expression was sufficient to induce the full activation of caspases. Bclxl expression levels in EOC cells is dynamic and can be regulated by microenvironments that are enriched with the pro-inflammatory cytokine IL-6 such as the cancer stem cell and adipocyte niches. PMID: 28012060
12. Study reports the interaction of BCL-XL with RASSF6. BCL-XL inhibits the interaction between RASSF6 and MDM2 and suppresses p53 expression. Consequently, BCL-XL antagonizes RASSF6-mediated apoptosis. Thus, the inhibition of RASSF6-mediated apoptosis also underlies the prosurvival role of BCL-XL. PMID: 29193479
13. These results show that mRNA expression in centenarians is unique and reveals that Bcl-xL plays an important role in exceptional aging. PMID: 27794564
14. that Ubiquitin-specific peptidase 18 directly bind to BCL2L1 and positively regulated its expression in hepatocellular carcinoma cells PMID: 28709980
15. High BCL-XL expression is associated with breast cancer. PMID: 28223545
16. The the expression of the full-length, wildtype form of PRMT2 promotes an increase in the BCL-X(L)/BCL-X(s) ratio in TNF-alpha or LPS stimulated cells. PMID: 28057797
17. Bcl-xL is a driver in colorectal tumorigenesis and cancer progression. PMID: 27537525
18. These data show that Mcl-1 is dispensable for the regulation of apoptosis during infection with different large DNA viruses.Bcl-XL, on the other hand, can be important to maintain survival of virus-infected cells PMID: 27537523
19. BC200 knockout suppresses tumor cell growth in vitro and in vivo by expression of the pro-apoptotic Bcl-xS isoform. PMID: 27277684
20. Bcl-xL inhibits GAS-induced autophagy directly by suppressing autophagosome-lysosome fusion and indirectly by suppressing GAS internalization via interaction with Beclin 1-UVRAG. PMID: 28085926
21. The combination of 2-deoxyglucose (2-DG) and ABT-199 initiated cell death through the reduction of myeloid cell leukemia sequence 1 protein (Mcl-1) expression and c-Jun N-terminal kinase 1 (JNK1) activation and subsequent Bcl-xL protein degradation. PMID: 28038464
22. Bcl-xL is an exosomal caspase-3 substrate and that this processing is required for the uptake of exosomes by recipient cells. PMID: 27742710
23. dynamic Bcl-xL(S49) and (S62) phosphorylation/dephosphorylation cycles are important in the maintenance of chromosome integrity during mitosis in normal cells PMID: 27398719
24. Mono treatment with lexatumumab was not sufficient to induce apoptosis in pancreatic cancer cells, whereas focal adhesion kinase inhibitor PF573228 significantly sensitized lexatumumab-induced apoptosis. Western blotting analysis revealed that lexatumumab and PF573228 combination treatment increased death receptor 5 but decreased Bcl-xL expression. PMID: 28459212
25. Reduced lifetimes of the donor were partially restored by coexpression of HIF-1alpha or Bcl-xL, binding proteins of IPAS in the nucleus and mitochondria, respectively. PMID: 28003430
26. mechanistic studies, inhibition of SRC and PKCdelta completely ablated the ability of MDA-7/IL-24 to reduce the Bcl-x(L)/(s) mRNA ratio and cell viability. These findings show that Bcl-x(s) expression is an important mediator of MDA-7/IL-24-induced cytotoxicity requiring the SRC/PKCdelta signaling axis in NSCLC cells. PMID: 27519412
27. Resistance induced in newly formed cancer stem cells is mediated by the anti-apoptotic molecule BCL-XL and inhibition of BCL-XL with the BH3 mimetic ABT-737 sensitizes these cancer cells toward chemotherapy. PMID: 25483065
28. we discovered that deletions involving the PARK2 gene are significantly anti-correlated with focal amplifications of the gene encoding BCL-XL. PMID: 28038320
29. The C-terminal tail of BCL-XL forms a membrane-embedded alpha-helix that anchors the protein's globular head to the lipid bilayer membrane, yet retains a significant degree of conformational dynamics. PMID: 26923059
30. Bcl-xL overexpression may be closely related to the dynamic of the pathogenesis and development of tongue carcinoma. PMID: 25550772
31. Results provide evidence that microRNA 421 induces apoptosis of cervical cancer cells via down-regulation of Bcl-xL. PMID: 27886335
32. We conclude that Bcl-x plays a role in regulation of HSC apoptosis and modulation of Bcl-x alternative splicing may become a novel molecular therapy for liver fibrosis. PMID: 27579319
33. Intracellular expression of Bcl-xL was significantly greater in CD4+ T-cells, CD8+ T-cells, and NK cells of infants with bronchiolitis compared to controls. PMID: 26541527
34. Data indicate the potential of functionalized Apt-carbon nanotubes conjugates for increasing the induction of apoptosis in Mucin-1 (MUC1) positive tumor cells by suppression of Bcl-xL transcript. PMID: 26731195
35. Genetic and pharmacological inhibition of BCL-W and BCL-XL causes directed elimination of senescent cells. PMID: 27048913
36. miR-133a and miR-326 downregulate the mRNA expression of Bcl-xl in HepG2 cells. PMID: 26239225
37. Bcl-xL is a key factor in polyploidization resistance in acute myeloid leukemia PMID: 26188358
38. This study lends new molecular insights into understanding the binding specificity of BH3 ligands to BclXL with important consequences on the design of novel anticancer drugs. PMID: 24114183
39. TCERG1 sensitizes a cell to apoptotic agents, thus promoting apoptosis by regulating the alternative splicing of both the Bcl-x and Fas/CD95 genes. PMID: 26462236
40. Data show that JAK/STAT signaling inhibition is potentiated by Bcl-xL (B-cell lymphoma-extra large) blockade in interleukin 2 (IL-2) dependent adult T-cell leukemia cells. PMID: 26396258
41. Data suggest BCL2-like 1 protein (BCL2L1) and deleted in liver cancer 1 protein (DLC1) as potential druggable targets for specific subsets of gastric cancer (GC) cases. PMID: 26401016
42. CD40 signaling led to sustained ERK1/2 activation and up-regulation of Bcl-xL in BCR-primed HF1A3 germinal center B cells.[BCR] PMID: 26054744
43. miR-326 targets antiapoptotic Bcl-xL and mediates apoptosis in human platelets. PMID: 25875481
44. alpha4 is an important regulatory molecule of apoptosis and Bcl-xL phosphorylation induced by BCR crosslinking. PMID: 25876659
45. These findings suggested that Bcl-xL may be a promising therapeutic approach for the treatment of NSCLC PMID: 25683634
46. Weakening the inhibition of either Bax or ceramide channels decreased the ability of Bcl-xL to protect cells from apoptosis in a stimulus-dependent manner. PMID: 26215742
47. BCL-XL up-regulation by STAT3 contributes to mutant KRAS-mediated apoptosis resistance. Such resistance can be overcome by potent BIM induction and concurrent BCL-XL antagonism PMID: 26245900
48. BCL2L1 mutation mediates copy number variant 20q11.21 in hESC lines. PMID: 24286026
49. We conclude that enhanced Bcl-xL levels confer resistance to cells upon epithelial to mesenchymal transformation PMID: 25473892
50. the combination of simultaneous siRNA-mediated knockdown of antiapoptotic Bcl-xL and survivin-a multitarget molecular-based therapy-and conventional chemotherapy shows great potential for improving bladder cancer treatment. PMID: 23749114
顯示更多

收起更多
亞細胞定位：

[Isoform Bcl-X(L)]: Mitochondrion inner membrane. Mitochondrion outer membrane. Mitochondrion matrix. Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane. Cytoplasm, cytosol. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Nucleus membrane; Single-pass membrane protein; Cytoplasmic side.
蛋白家族：

Bcl-2 family
組織特異性：

Bcl-X(S) is expressed at high levels in cells that undergo a high rate of turnover, such as developing lymphocytes. In contrast, Bcl-X(L) is found in tissues containing long-lived postmitotic cells, such as adult brain.
數(shù)據(jù)庫鏈接：

HGNC: 992

OMIM: 600039

KEGG: hsa:598

STRING: 9606.ENSP00000302564

UniGene: Hs.516966

Most popular with customers

YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human